RT Journal Article
SR Electronic
T1 Lesions in putative language and attention regions are linked to more severe strokes in patients with higher white matter hyperintensity burden
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.11.05.21265496
DO 10.1101/2021.11.05.21265496
A1 Bonkhoff, Anna K.
A1 Hong, Sungmin
A1 Bretzner, Martin
A1 Schirmer, Markus D.
A1 Regenhardt, Robert W.
A1 Arsava, E. Murat
A1 Donahue, Kathleen L.
A1 Nardin, Marco J.
A1 Dalca, Adrian V.
A1 Giese, Anne-Katrin
A1 Etherton, Mark R.
A1 Hancock, Brandon L.
A1 Mocking, Steven J. T.
A1 McIntosh, Elissa C.
A1 Attia, John
A1 Benavente, Oscar R.
A1 Cole, John W.
A1 Donatti, Amanda
A1 Griessenauer, Christoph J.
A1 Heitsch, Laura
A1 Holmegaard, Lukas
A1 Jood, Katarina
A1 Jimenez-Conde, Jordi
A1 Kittner, Steven J.
A1 Lemmens, Robin
A1 Levi, Christopher R.
A1 McDonough, Caitrin W.
A1 Meschia, James F.
A1 Phuah, Chia-Ling
A1 Rolfs, Arndt
A1 Ropele, Stefan
A1 Rosand, Jonathan
A1 Roquer, Jaume
A1 Rundek, Tatjana
A1 Sacco, Ralph L.
A1 Schmidt, Reinhold
A1 Sharma, Pankaj
A1 Slowik, Agnieszka
A1 Söderholm, Martin
A1 Sousa, Alessandro
A1 Stanne, Tara M.
A1 Strbian, Daniel
A1 Tatlisumak, Turgut
A1 Thijs, Vincent
A1 Vagal, Achala
A1 Wasselius, Johan
A1 Woo, Daniel
A1 Zand, Ramin
A1 McArdle, Patrick F.
A1 Worrall, Bradford B.
A1 Jern, Christina
A1 Lindgren, Arne G.
A1 Maguire, Jane
A1 Golland, Polina
A1 Bzdok, Danilo
A1 Wu, Ona
A1 Rost, Natalia S.
A1 ,
YR 2021
UL http://medrxiv.org/content/early/2021/11/09/2021.11.05.21265496.abstract
AB Objective To examine whether high white matter hyperintensity (WMH) burden is associated with greater stroke severity and worse functional outcomes in lesion pattern-specific ways.Methods MR neuroimaging and National Institutes of Health Stroke Scale data at index stroke, as well as modified Rankin Scale (mRS) at 3-6 months post-stroke were obtained from MRI-GENIE study of acute ischemic stroke (AIS) patients. Individual WMH volume was automatically derived from FLAIR-images. Stroke lesions were automatically segmented from DWI-images, spatially normalized and parcellated into atlas-defined brain regions. Stroke lesion effects on AIS severity and unfavorable outcomes (mRS>2) were modeled within a purpose-built machine learning and Bayesian regression framework. In particular, interaction effects between stroke lesions and a high versus low WMH burden were integrated via hierarchical model structures. Models were adjusted for the covariates age, age2, sex, total DWI-lesion and WMH volumes, and comorbidities. Data were split into derivation and validation cohorts.Results A total of 928 AIS patients contributed to stroke severity analyses (mean age: 64.8(14.5), 40% women), 698 patients to functional outcome analyses (mean age: 65.9(14.7), 41% women). Individual stroke lesions were represented in five anatomically distinct left-hemispheric and five right-hemispheric lesion patterns. Across all patients, acute stroke severity was substantially explained by three of these patterns, that were particularly focused on bilateral subcortical and left-hemispherically pronounced cortical regions. In high WMH burden patients, two lesion patterns consistently emerged as more pronounced in case of stroke severity: the first pattern was centered on left-hemispheric insular, opercular and inferior frontal regions, while the second pattern combined right-hemispheric temporo-parietal regions. Bilateral subcortical regions were most relevant in explaining long term unfavorable outcome. No WMH-specific lesion patterns of functional outcomes were substantiated. However, a higher overall WMH burden was associated with higher odds of unfavorable outcomes.Conclusions Higher WMH burden increases stroke severity in case of stroke lesions involving left-hemispheric insular, opercular and inferior frontal regions (potentially linked to language functions) and right-hemispheric temporo-parietal regions (potentially linked to attention). These findings may contribute to augment stroke outcome predictions and motivate a WMH burden and stroke lesion pattern-specific clinical management of AIS patients.Competing Interest StatementM.E. has received personal fees for consulting from Astra Zeneca and WorldCare Clinical Group. C.G. has received consulting honoraria from Microvention and Strykere and research funding from Medtronic and Penumbra. A.V. has received research funding from Cerenovus. A.L. has received personal fees from Bayer, Astra Zeneca, BMS Pfizer, and Portola. T.T. has served/serves on scientific advisory boards for Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Inventiva, Portola Pharm, and PHRI; has/ has had research contracts with Bayer, Boehringer Ingelheim, and Bristol Myers Squibb. N.S.R. has received compensation as scientific advisory consultant from Omniox, Sanofi Genzyme and AbbVie Inc.Funding StatementA.K.B. is supported by a MGH ECOR Fund for Medical Discovery (FMD) Clinical Research Fellowship Award. M.B. acknowledges support from the Societe Francaise de Neuroradiologie, Societe Francaise de Radiologie, Fondation ISITE-ULNE. A.V. is in part supported by NIH-NINDS (R01 NS103824, RF1 NS117643, R01 NS100417, U01NS100699, U01NS110772). C.L, JA have been funded by the National Health and Medical Research Council (Australia) Project Grant ID. 1023799. A.G.L. acknowledges support from the Swedish Research Council (2019-01757), The Swedish Government (under the Avtal om Laekarutbildning och Medicinsk Forskning, ALF), The Swedish Heart and Lung Foundation, Region Skane, Lund University, Skane University Hospital, Sparbanksstiftelsen Faers och Frosta, Fremasons Lodge of Instruction Eos in Lund and NIH (1R01NS114045-01). P.G. is supported by NIH NIBIB NAC P41EB015902. D.B. has been funded by the Brain Canada Foundation, through the Canada Brain Research Fund, with the financial support of Health Canada, National Institutes of Health (NIH R01 AG068563A), the Canadian Institute of Health Research (CIHR 438531), the Healthy Brains Healthy Lives initiative (Canada First Research Excellence fund), Google (Research Award, Teaching Award), and by the CIFAR Artificial Intelligence Chairs program (Canada Institute for Advanced Research). N.S.R. is in part supported by NIH-NINDS (R01NS082285, R01NS086905, U19NS115388).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Patients gave written informed consent in accordance with the Declaration of Helsinki. The study protocol was approved by Massachusetts General Hospitals Institutional Review Board (Protocol #: 2001P001186 and 2003P000836).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe authors agree to make the data of development and validation cohorts available to any researcher for the express purposes of reproducing the here presented results, and with the explicit permission for data sharing by Massachusetts General Hospitals institutional review board.AFatrial fibrillationAUCarea under the curveCADcoronary artery diseaseDMdiabetes mellitusHTNhypertensionNIHSSNational Institutes of Health Stroke ScaleNMFnon-negative matrix factorizationmRSmodified Rankin ScalePCAposterior cerebral arteryWMHwhite matter hyperintensities